Craniopharyngioma With Tumoral Hemorrhage

Sponsor

Tongji Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT04937335

Collaborator

(none)

185

Enrollment

Actual Duration (Months)

Study Details

Study Description

Brief Summary

Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected. Among these patients, 18 of them were recognized as craniopharyngioma with tumoral hemorrhage during the operation.

Condition or Disease	Intervention/Treatment	Phase
Craniopharyngioma Apoplexy	Other: intratumoral hemorrhage

Detailed Description

For each case, age, gender, smoking status, alcohol intake, past history, symptoms, blood pressure, blood cell count, blood biochemical tests, coagulation tests, hormone tests, radiological results, surgical treatment and the outcome at discharge were collected. The first test result after admission and before the operation was taken for the items of blood tests with multiple times in the analysis.

Study Design

Study Type:

Observational

Actual Enrollment :

185 participants

Observational Model:

Case-Control

Time Perspective:

Retrospective

Official Title:

Clinical Features and Risk Factors of Craniopharyngioma With Tumoral Hemorrhage

Actual Study Start Date :

Jan 1, 2013

Actual Primary Completion Date :

Feb 1, 2021

Actual Study Completion Date :

Feb 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Non-hemorrhage group Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation
Hemorrhage group Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation	Other: intratumoral hemorrhage Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.

Arm

Intervention/Treatment

Non-hemorrhage group

Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation

Hemorrhage group

Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation

Other: intratumoral hemorrhage

Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.

Outcome Measures

Primary Outcome Measures

craniopharyngioma with tumoral hemorrhage [during the operation]
Current study is a case-control study whose primary outcome is tumoral hemorrhage observed during the operation, which devided the craniopharyngioma patients into hemorrhage group and non-hemorrhage group.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

receive resective operation with a pathological diagnosis of craniopharyngioma in our hospital
enter our hospital between January 2013 and February 2021

Exclusion Criteria:

have a non-craniopharyngioma or unverified pathological diagnosis at discharge
have received surgical or radiological treatment on the sellar region
receive treatment of coagulation modulation, immunosuppressive agents or chemotherapeutic drugs
combine with other clinical emergencies including acute myocardial infarction, cerebral stroke, trauma and sepsis at admission
have been diagnosed with other tumors, hematological diseases, autoimmune diseases, liver failure or renal failure